Orexin-A vs Cotadutide
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Orexin-A | Cotadutide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | Hypocretin-1 (Orexin-A) | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | 3562 Da | ~4,700 Da |
| Half-Life | Minutes to <1 hour | Approximately 24 hours |
| Amino Acids | 33 | 37 |
| Typical Dose | Research-only; no validated human dose | 0.3-3 mg daily in clinical studies |
| Route | Intracerebroventricular/Intranasal | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 18 |
| Research Status | Pre-clinical | Clinical |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.